ABBV
AbbVie just got a pipeline pep rally
AbbVie is out with positive topline results from its Phase 3 CERVINO trial, and the headline is simple: etentamig looked better than standard available therapies in patients with relapsed/refractory multiple myeloma. The company said the drug delivered a 74% objective response rate and cut the risk of disease progression or death by 60%.
Why investors should care
This is the kind of readout that can move a pipeline from “interesting science” to “okay, now we’re talking revenue potential.” Etentamig is a second-generation BCMA-directed T-cell engager, which is biotech-speak for a therapy that could matter in a crowded but valuable cancer market.
AbbVie also highlighted a few practical perks that matter outside the lab coat crowd:
- low rates of cytokine release syndrome
- low fatal infections
- monthly dosing after a single step-up dose
That combo matters because drugs that work and are easier to use have a much better shot at getting traction with doctors, patients, and insurers. Nobody wants a miracle therapy that feels like a part-time job.
The bigger picture
This won’t hit the market overnight, and topline data are still just the opening act. But for AbbVie, strong late-stage oncology data can help diversify the story beyond its legacy blockbuster machine. Big picture: if etentamig keeps this momentum, AbbVie could have another serious shot at turning pipeline hype into actual earnings power.